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Abstract:  Antimicrobial  peptides  constitute  a  diverse  class  of  naturally  occurring 
antimicrobial  molecules  which  have  activity  against  a  wide  range  of  pathogenic 
microorganisms. Antimicrobial peptides are exciting  leads  in the development of novel 
biocidal  agents  at  a  time  when  classical  antibiotics  are  under  intense  pressure  from 
emerging  resistance,  and  the  global  industry  in  antibiotic  research  and  development 
stagnates. This review will examine the potential of antimicrobial peptides, both natural 
and  synthetic,  as  novel  biocidal  agents  in  the  battle  against  multi-drug  resistant  
pathogen infections.  
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1. Introduction 
1.1. Antimicrobial Peptides 
Despite continuing efforts, the increasing prevalence of resistance among pathogenic bacteria to 
common  antibiotics  has  become  one  of  the  most  significant  concerns  in  modern  medicine.  With 
significantly  reduced  investment  in  antimicrobials  research  and  development  among  major 
pharmaceutical companies, novel alternatives to existing treatment strategies are not being produced at 
a sufficient rate to keep pace with the emergence of resistance and the supply pipeline runs perilously 
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close to drying up [1]. Incidences of hospital-acquired and community-acquired antibiotic resistant 
Staphylococcus  aureus  infections  have  risen  dramatically  in  recent  years  [2],  with  almost  50% of 
hospital  acquired  Staphylococcus  aureus  infections  classified  as  methicillin  resistant  and  30%  of 
enterococci exhibiting vancomycin resistance [3]. In 2010, the Infectious Diseases Society of America 
launched its 10 × 20 initiative, calling for a global commitment to new antibacterial drug development, 
with the goal of ten new antibiotic agents by the year 2020 [4]. In addition, continued extensive use of 
the limited classes of effective antibiotics currently available threatens to call time on the ‘antibiotic 
era’. In the past decade, the crisis of antimicrobial resistance has worsened significantly and there 
exists an urgent requirement for new antimicrobial  agents with activity against multidrug resistant 
pathogens [5].  
One area of antimicrobial drug research that does shows significant promise is in the discovery and 
development of antimicrobial peptides (AMPs). Antimicrobial peptides in nature serve as important 
defensive weapons throughout the animal and plant kingdoms against a broad spectrum of bacterial 
and  fungal  pathogens  [6].  Sources  range  from  single  celled  microorganisms,  such  as  bacteria 
themselves  (bacteriocins)  [7],  to  invertebrates  [8].  As  well  as  having  a  direct  effect  on  the 
microorganism, antimicrobial peptides have been proven to promote the accumulation of immune cells 
including  macrophages,  neutrophils  and  lymphocytes  [9];  neutralize  lipopolysaccharide  endotoxin 
derived from Gram-negative bacteria [10]; aid wound repair; stimulate angiogenesis [11] and control 
the  actions  of  the  innate  and  adaptive  immune  response  with  little  or  no  resistance  development 
reported.  Antimicrobial peptides exert their microbicidal effect via disruption of the microbial cell 
membrane together with intracellular action [12,13].  
Antimicrobial peptides are short (typically ranging from 12–100 amino acid residues in length), 
exhibit rapid and efficient antimicrobial toxicity against a range of pathogens [14,15] and constitute 
critical  effector  molecules  in  the  innate  immune  system  of  both  prokaryotic  and  eukaryotic  
organisms [16]. To date, over 1700 endogenous antimicrobial peptides have been isolated with many 
more synthetic analogues reported in the literature [17]. Structure activity relationship analyses have 
yielded  vital  information  relating  to  the  structural  features  of  effective  antimicrobial  peptides, 
indicating that antimicrobial activity is governed primarily by charge and hydrophobicity [18], and that 
the  initial  target  is  the  negatively  charged  bacterial  cell  membrane  [19].  These  studies  have  also 
facilitated the design of ultrashort, highly active antimicrobial peptide scaffolds [20,21] which may be 
prepared via established  facile, solid phase synthetic protocols at lower costs compared with their 
natural antimicrobial peptide counterparts [22,23].  
1.2. Cationic Antimicrobial Peptides 
The majority of antimicrobial peptides are cationic with more than a thousand characterized and are 
thus  termed  cationic  antimicrobial  peptides  (CAPs)  [24].  Naturally  derived  cationic  antimicrobial 
peptides typically consist of a net positive charge between +2 and +9, due to the presence of few or no 
acidic residues, such as glutamate or aspartate and a high number of cationic amino acids such as 
lysine  or  arginine  and/or  histidine  [25].  Hydrophobic  residues,  including  tryptophan  and  branched 
amino  acids  such  as  valine,  form  30–50%  of  the  total  peptide  structure  and  serve  a  vital  role  in 
allowing  a  typical  amphiphilic  structure  to  form  upon  interaction  with  membranes  [26].  This Int. J. Mol. Sci. 2011, 12                       
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characteristic  together  with  the  presence  of  dense  areas  of  high  positive  charge  allow  cationic 
antimicrobial peptides to exert their antimicrobial effect. Alteration of this net charge to hydrophobic 
ratio can vary the activity and spectrum of the peptide against a host of microorganisms. The increase 
in activity that can be therapeutically achieved by tapering the lipophilic:charge ratio is provided by 
the example of glycopeptides. Glycopeptides, for example vancomycin, represent one of the last line of 
effective antibiotics against Methicillin resistant Staphylococcus aureus. Lipoglycopeptide derivatives 
of vancomycin in development include oritavancin and dalbavancin which possess increased activity 
against vancomycin-resistant strains [27]. Slight modifications in the balance of hydrophobicity and 
charge can give rise to marked changes in antimicrobial selectivity/activity [28]. Cationic antimicrobial 
peptides, as a class of compounds, have broad structural diversity and antimicrobial spectrum influenced 
primarily by the amino acids that constitute the primary sequence of the peptide [29]. 
Although the secondary structures that antimicrobial peptides adopt may vary between classes they 
share  the  same  characteristic  of  developing  an  amphipathic  structure  and  being  cationic  under 
physiological conditions [30,31]. Secondary structures include amphiphilic β-sheet structures containing 
two or three stabilizing disulphide bonds, often  with a short α-helical segment and/or two to four  
β-strands. These disulphide bridges form as a result of a cysteine-rich primary sequence. Examples of 
these  peptides  in  nature  include  several  classes  of  mammalian  host  defense  peptides  including  
α-defensin  and  β-defensin  [32].  Linear  peptides  are  unordered  in  hydrophilic  solutions  but  form 
amphipathic α-helices upon contact with cell membranes and in a hydrophobic environment [33].  
These peptides are of particular interest as one face of the helix structure contains a majority of 
hydrophobic residues whereas the opposite face contains mainly polar amino acids allowing efficient 
solubilization of microbial membranes [26]. Amphipathic α-helices lack cysteine and are thus unable 
to  form  disulphide  bridges  [34].  Examples  in  nature  include  mellitin  derived  from  honeybee  
venom [35], magainin obtained from the skin secretions of the frog species Xenopus laevis [36] and the 
cecropins, a group of the dipteran insect defense peptides [37]. Cyclic peptides are a less prevalent 
structural class of cationic antimicrobial peptides that contain β-turn influenced by a single disulphide 
bond and include a dodecapeptide from bovine neutrophils [38].  
Extended structures with a  high regularity of one or two amino acid residues,  such as proline, 
glycine, histidine or tryptophan, make up the remainder of the four major structural varieties [15,39]. 
Extended cationic peptides have no defined or typical structure due to the existence of novel folds. 
Examples  in  nature  include  the  porcine  derived  tritrpticin  [40]  and  the  bovine  neutrophil  peptide 
indolicidin [41]. Indolicidin is a linear antimicrobial peptide consisting of a 13 amino acid structure 
high in tryptophan residues (~40%) [42]. Both these peptides form boat-like structures in the presence 
of  cell  membranes  as  the  high  tryptophan  content  interacts  with  the  hydrophobic  layer  of  the 
membrane with the remaining cationic arginine and lysine residues orientated towards the aqueous 
environment [43]. The cationic AMP mimetic tyrocidin was the first commercially available antibiotic. 
However major issues with toxicity toward human blood and reproductive cells lead to its withdrawal 
from the market [44]. The polypeptide bacitracin has had a more successful introduction clinically 
incorporated with both neomycin and polymyxin B in the topical product Neosporin® licensed for the 
topical treatment of a variety of localized skin and eye infections [45].  Int. J. Mol. Sci. 2011, 12                       
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1.3. Anionic Antimicrobial Peptides 
Despite the vast majority of antimicrobial peptides being cationic in nature, a significant number of 
anionic AMPs have been reported; serving as important weapons in the eukaryotic innate immune 
response [46–48]. Peptides that are anionic in nature tend to be rich in glutamic and aspartic acids and 
include  the  amphibian  peptide  Maximin-H5  and  Dermcidin,  a  peptide  derived  from  human  
sweat  [49,50].  Anionic  antimicrobial  peptides  commonly  consist  of  5  to  70  amino  acid  residues, 
possessing  a  net  charge  of  −1  or  −2  although  structural  characterization  demonstrated  that  the 
truncated form of bovine peptide B, termed enkelytin, can possess a net charge as high as −7 [48,51]. 
Although  less  common,  anionic  peptides  of  300  residues  in  length  and  net  charge  −20  have  been  
reported [52–54].  Similarly to their cationic counterparts, anionic antimicrobial peptides can adopt 
varying amphiphilic structures such as the α-helix and the β-sheet conformations with interaction with 
the microbial membrane key to activity.  
A  disadvantage  of  many  anionic  antimicrobial  peptides  is  that  they  often  require  cations,  for 
example zinc (Zn
2+), as cofactors for biocidal activity [55]. This may be why they are generally located 
at epithelia; sites were both ionic secretion and microbial susceptibility are highest. Anionic peptides, 
for example surfactant-associated anionic peptides present in pulmonary tissue, have been shown to 
possess increased potency against both Gram-positive and Gram-negative bacteria in the presence of 
synergistic cationic antimicrobial peptides and Zn
2+ [56,57]. These cationic moieties act as a cationic 
linkage between the anionic antimicrobial peptide and the anionic microbial cell membrane. This allows 
transport  of  the  anionic  peptide  to  intracellular  targets  without  damaging  to  the  structure  of  the 
microbial membrane [55,58]. Anionic peptides target ribosomes within the cell inhibiting ribonulease 
activity, thus resulting in microbial cell death [59,60].  
1.4. Amphibian Antimicrobial Peptides 
Amphibian  derived  peptides  are  excellent  examples  of  naturally  occurring,  structurally  diverse 
peptides with high antimicrobial potency. These compounds are released in skin secretions often at 
high concentrations and their production reflects the evolution of amphibians to their humid habitat, an 
environment also suitable for the growth and proliferation of opportunistic pathogenic bacteria and 
fungi  [61].  Such  peptides  are  also  beginning  to  show  promise  against  cancer,  as  anti-tumor  
compounds [62] and also possess anti-viral activity, with potential benefits against HIV [63]. They 
also show activity against eukaryotic cells and therefore provide a means by which amphibians may be 
protected  from  predation  [64].  The  potential  therefore  exists  that  amphibian  derived  antimicrobial 
peptides may also be cytotoxic to humans. Such peptides are released naturally in response to injury or 
stress  via  contraction  of  myocytes  surrounding  the  glands  [65]  and  this  may  be  replicated  in  the 
laboratory  through  the  use  of  mild  electrical  stimulation  [66]  or  injecting  norepinephrine  into the 
dorsal sac [67].  
Structural  characterization  has  facilitated  their  synthetic  production  via  solid  phase  peptide 
synthesis (SPPS). In frogs, variations in the sequence and spectrum of activity of these peptides are 
considerable  with  hundreds  of  characterized  peptides  providing  protection  against  a  vast  range  of 
bacterial and fungal species [61,68,69]. The majority of antimicrobial peptides from frogs are cationic Int. J. Mol. Sci. 2011, 12                       
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due to a high presence of lysine, with at least 50% of amino acids being hydrophobic of which leucine 
is most prevalent and an amphipathic α-helix secondary structure predominates at the cell membrane  
interface [61,70]. Relevant genera of frog studied include Bombina [71], Xenopus [36], Rana [72], 
Phyllomedusa [73] and Litoria [74]. The species Bombina maxima, commonly known as the Chinese 
red  belly  toad  has  as  many  as  forty  genes  linked  to  the  production  of  different  antimicrobial  
peptides [75]. Research conducted by Lai et al. showed that Bombina maxima produced a group of 
peptides called maximins that demonstrated minimum inhibitory concentration (MIC) values in the 
µg/mL range against a broad spectrum of microbial and fungal pathogens including Staphylococcus 
aureus,  Escherichia  coli,  Bacillus  dysenteriae,  Klebsiella  pneumoniae  and  Candida  albicans  [76]. 
Both  maximin-3  and  maximin-4  were  the  most potent  peptides  tested  with  maximin-4  having  the 
lowest MIC value of 2.7 µg/mL against Staphylococcus aureus. Maximin-4 consists of twenty seven 
amino acids and has the potential to be produced synthetically via SPPS. Dermaseptins are a family of 
linear lysine-rich cationic antimicrobial peptides derived from the genus Phyllomedusa. They consist 
of between twenty eight and thirty four amino acid residues and have been shown to inhibit the growth 
of a wide variety of Gram-positive and Gram-negative bacteria, fungi, protozoa and yeast [73,77].  
1.5. Rational Design and Selection of an Antimicrobial Peptide Motif 
The diverse range of antimicrobial peptides available in nature provides a vast scope for the design 
of novel and improved synthetic variations. Structure and its effect on the hydrophobic:charge ratio is 
more important with regard to antimicrobial activity than size and the manipulation of primary amino 
acid  sequence  can  improve  factors  such  as  specificity,  toxicity  and  stability  [12,78].  Ultrashort 
antimicrobial peptides consist of approximately four or five amino acids residues, with amino acid 
selection fulfilling the minimum range of functionalities required for effective antimicrobial activity. 
These functionalities include a charged moiety such as arginine and a lipophilic unit, most commonly 
tryptophan,  forming an antimicrobial pharmacophore with the correct balance  between charge and 
lipophilicity [79].  
Strom et al. have proven that tryptophan provides better bulk and lipophilicity than tyrosine and a 
minimum of two bulk and two charged residues are required to be present to give activity against 
staphylococci,  with  Escherichia  coli  requiring  an  additional  bulk  tryptophan.  Arginine  also  acts  a 
better source of charge than lysine within the minimum motif [78]. However arginine is difficult to 
work with in terms of SPPS [80,81]. The obvious advantage to the use of ultrashort antimicrobial 
peptide is the large reduction in cost in synthesizing these molecules relative to synthetic variants of 
naturally  occurring  antimicrobial  peptides.  The  attachment  of  an  acyl  chain  to  an  active  or  inert 
ultrashort cationic peptide also potentially leads to an increased action against microorganisms in a 
similar way to native cationic antimicrobials [82]. Small alterations of the total methylene units present 
can also modify the spectrum of activity for the antimicrobial, the cell specificity and therefore levels 
of hemolysis [83]. Previous studies by Makovitski et al. reported however that peptides containing 
four amino acids would find it difficult to form a characterized, stable amphipathic structure, therefore 
questions still relate to their mode of action. Reported results also show that the balance of hydrophobicity 
and charge play an important role just as in the larger antimicrobial peptides. By altering both, the Int. J. Mol. Sci. 2011, 12                       
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amino acid residues and the acyl chain  length, it was found that increasing hydrophobicity and/or 
charge is not necessarily indicative to increasing antimicrobial function [84].  
Host and  microbial proteases and the unfavorable pharmacokinetics they  bring present a  major 
barrier to the use of peptides as antimicrobials in vivo, with many peptides limited to use as topical 
applications. Human chymotrypsin-like enzymes function at basic amino acid residues [85], therefore 
antimicrobial peptides are a viable target due to the requirement of basic residues to be present for 
antimicrobial activity. Simple α-helical or linear structures in particular are susceptible to proteolysis 
by a range of microbial proteases [86]. As proteases will only recognize natural L-amino acid residues, 
a switch to the use of D-amino acids at susceptible points will render the peptide partially or totally 
resistant to proteolysis without loss of antimicrobial activity [87]. L-stereoisomers also tend to be more 
hemolytic than their D counterparts [88]. Antimicrobial peptides are expensive to synthesize and costs 
are increased further by the use of D-enantiomers thus a more viable alternative is to select unnatural 
amino acids, such as ornithine. The use of ornithine as a charged moiety is preferable as the use of a 
non-coded amino acid provides stability against proteases [78]. Examples of synthetic harnessing of 
ornithine’s  properties  are  demonstrated  by  Bisht  et  al.  They  demonstrated  the  potent  action  of 
ultrashort  tetrapeptides  with  two  ornithines  representing  the  charged  portion  and  two  tryptophans 
providing bulk and hydrophobicity [21]. Modification occurred with conjugation of cinnamic groups to 
the N
α-amino terminus of ornithine. The incorporation of ornithine into the lipopeptide scaffold has 
also been tested in the synthetic peptide MSI-843 [89]. Containing six ornithine residues out of a total 
ten  and  a  conjugated  octanyl  terminus,  excellent  activity  was  shown  against  Gram-positive 
Staphylococcus aureus; Gram-negative Pseudomonas aeruginosa and Escherichia coli and the fungus 
Candida albicans.  
1.6. Ultrashort Cationic Antimicrobial Peptides 
Ultrashort  cationic  antimicrobial  peptides  consist  of  approximately  four  or  five  amino  acids 
residues, with amino acid selection fulfilling the minimum range of properties required for effective 
antimicrobial  activity  to  take  place.  The  use  of  ultrashort  cationic  antimicrobial  peptides  is 
advantageous  in  terms  of  manufacture  with  reduced  production  costs  and  synthesis  times.  
Their production correlates to a trend amongst peptide companies that has seen an increase in the 
production of these smaller peptides in relation to larger, more expensive natural peptides [90,91]. 
Haug  and  colleagues  discovered,  using  lactoferrin  derivatives,  that  a  minimum  motif  existed  for 
antibacterial action against many forms of bacteria including strains of Staphylococcus aureus resistant 
to common antibiotic regimens [79,92–97]. Of high importance to their activity is the overall balance 
between  lipophilicity and charge with the presence of two units of bulk and two cationic charges 
mandatory  for  membrane  interaction  and  antimicrobial  activity  [16,78].  Naturally  occurring 
antimicrobial  peptides  have  a  largely  lipophilic  character  with  the  primary  sequence  consisting  of  
30–50%  bulky  hydrophobic  residues  such  as  tryptophan  [26].  Tetra  and  pentapeptides  possess  a 
relatively small pharmacophore with limited bulk, thus in order to produce a favorable increase in the 
lipophilicity to charge ratio the amino terminus is acylated with a variety of hydrocarbon moieties [98]. 
With this knowledge Haug et al. produced a series of smaller dipeptides of a general formula XRY 
where;  X  represented  a  variant  of  a  bulky  amino  acid  with  a  lipophilic  side  chain,  for  example Int. J. Mol. Sci. 2011, 12                       
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cyclohexylalanine; R represented arginine, the charged moiety; Y represented a C-terminal ester or a 
lipophilic  amide  derivative  [79].  Both  X  and  Y  provided  bulk  to  the  short  pharmacophore.  
A 2,5,7-tri-tert-butyl-tryptophan-arginine-benzyl amide was shown to be the most active peptide in the 
study. This structure correlates with the minimum requirement for two units of bulk, provided by the 
tryptophan derivative  and  benzene ring of the  benzyl amide  and two units of charge  imparted  by 
arginine’s guanidino group and the free N
α-amino terminus. Central to this theory Bisht et al. produced 
a series of ornithine and tryptophan containing tetrapeptides and evaluated them against planktonic 
forms of various Gram-positive and Gram-negative bacteria [21]. To increase hydrophobicity cinnamic 
acid and  its derivatives were attached to the amino terminus of the peptide  motif. These terminal 
carboxylic acids included cinnamic acid, 3,4-dimethoxycinnamic acid, 4-hydroxy cinnamic acid and  
3-(4-hydroxyphenyl) propionic acid. 
1.7. Lipopeptides 
Lipopeptides are essentially a peptide attached to a lipid moiety. Such a peptide may include an 
antimicrobial  peptide.  Native  lipopeptides  are  formed  in  bacteria  and  fungi  non-ribosomally  by 
cultivation on a range of carbon sources to form complex cyclic structures [99]. They normally consist 
of a sequence of six or seven amino acids with a N-terminal fatty acid moiety attached. They are active 
against a range of multi-resistant bacteria and fungi [100]. Antimicrobial lipopeptides are primarily 
bacterial compounds synthesized via non-ribosomal biosynthetic pathways and comprise a peptidyl 
portion  conjugated  to  a  fatty  acid  to  form  an  acylated  peptide  [99].  Many  naturally  occurring 
lipopeptides  are  cyclized  and  may  also  contain  unnatural  amino  acids  that  confer  stability  against 
proteolytic  degradation.  Lipopeptides  may  comprise  an  anionic  (e.g.,  Daptomycin,  surfactin)  or 
cationic (e.g., polymyxin B, colistin) peptide motif, which dictates the spectrum of activity [99]. Fatty 
acids, fatty amines, alcohols and gylceryl esters have all been shown to exhibit varying degrees of 
antimicrobial  activity  [101,102],  whilst  acylation  of  peptide  scaffolds  has  been  demonstrated  to 
significantly  improve  antimicrobial  activity  [99,103].  For  example  when  the  natural  occurring 
polymyxin  is coupled to a fatty acid tail,  removal of this tail  leads to a decrease in antimicrobial  
action [104]. The conjugation of a fatty acid moiety at the N-terminus can also compensate for a loss 
of hydrophobicity within the peptidic chain based on amino acid residue selection [105]. Therefore, the 
combination of an optimized peptidyl scaffold and N-terminal acyl substituent (i.e., fatty acid) with 
inherent  antimicrobial  activities  represents  an  approach  to  the  development  potent  antimicrobial 
agents, whereby spectrum of activity may be modulated via modification of the N-terminal substituent, 
whilst circumventing the commercial barriers associated with the manufacture of natural antimicrobial 
peptides in high yields.  
1.8. Licensed and Commercially Available Lipopeptides 
A  variety  of  anionic  and  cationic  lipopeptides  are  currently  licensed  for  commercial  use,  thus 
highlighting the clinical potential of these antimicrobials. These include daptomycin, polymyxin B and 
polymyxin E (colistin).  Int. J. Mol. Sci. 2011, 12                       
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1.8.1. Daptomycin 
Daptomycin  is  an  anionic  lipopeptide  that  is  produced  naturally  by  Streptomyces  roseosporus 
(Actinobacteria).  Daptomycin  is  a  cyclic  depsipeptide  consisting  of  thirteen  amino  acids,  which 
includes three D-amino acid residues (D-asparagine, D-alanine, and D-serine) linked to a hydrocarbon 
tail ten carbons in length derived from decanoic acid (Figure 1). Synthetic production of lipopeptides 
has led to the approval of the lipopeptide daptomycin which gained US and EU product licenses in 
2003 and 2006 respectively for skin and soft tissue infections [106]. More recently it has been passed 
for use in the US for staphylococcal bacteremia and right sided endocarditis [107]. Daptomycin is also 
available in the UK as an injection and is commercially available as the brand Cubicin
® with further 
research showing possible use in the treatment of enterococcal bacteremia caused by Enterococcus 
faecium and Enterococcus faecalis [108]. Daptomycin, itself anionic, is dependent on the presence of 
calcium cations for antimicrobial activity. Electrostatic interactions allow daptomycin to alter to an 
active conformation. Increased amphiphilicity and integration of daptomycin into bacterial membranes 
occurs via the acyl chains [109–113]. This results in the formation of micelle-like structures with the 
lipid  tails  of  daptomycin  pointing  inwards  and  the  anionic  side  groups  held  together  by  calcium  
ions  [114].  At  bacterial  membranes  these  micelles  dissociate  with  daptomycin  oligomerising  in  the 
membrane creating a potassium efflux ultimately resulting in; membrane disruption; cessation of the 
synthesis of the macromolecules Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA) and protein 
synthesis; eventually leading to cell death. Unlike β-lactams this process is cell lysis independent with 
only the cell membrane, not the cell wall, disrupted [115]. Generally, daptomycin is well tolerated, 
although myopathy has been reported in some patients [116]. 
Figure 1. The structure of Daptomycin. Adapted from Steenbergen et al. 2005 [113]. 
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1.8.2. Polymyxins (B and E) 
Polymyxins  are  a  group  of  cationic  antimicrobials  discovered  in  the  late  1940s  [117–119]. 
Polymyxin  E  was  later  identified  in  the  1950s  [120].  Polymyxins  are  N-terminally  fatty  acylated Int. J. Mol. Sci. 2011, 12                       
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cationic lipopeptides consisting of a cyclic peptide structure attached to a hydrocarbon tail. Removal of 
the fatty acid tail reduces the antimicrobial activity of polymyxin [104]. They are isolated naturally 
from the Gram-positive bacteria Bacillus polymyxia [121]. Only two polymyxins are commercially 
available, polymyxin B and polymyxin E (colistin) [122]. Polymyxin B is a cyclic heptapeptide with a 
tripeptide side chain that is acylated at its amino terminus by a fatty acid. Polymyxin B consists of the 
amino acids D-phenylalanine, L-threonine and L-α-γ-diaminobutyric acid [123,124]. Colistin has the 
same structure as polymyxin B but D-phenylalanine is replaced by D-leucine [124]. A range of topical 
and parenteral formulations are available indicated for the treatment of Gram-negative skin and eye 
infections, including those involving Pseudomonas aeruginosa, with a powdered nebulizer solution 
available to treat multidrug resistant Gram-negative infection in cystic fibrosis patients [125–127]. The 
mechanism of action of the polmyxins is similar to cationic antimicrobial peptides in general [128,129]. 
Interaction  of  the  hydrophobic  tail  with  lipopolysaccharides  present  on  the  outer  membrane  of  
Gram-negative  bacteria  creates  a  detergent-like  effect  compromising  the  integrity  of  the  bacterial 
membrane [130]. Polymyxins may also displace magnesium and calcium ions from cationic binding 
sites present at the bacterial cell surface resulting in leakage of cell contents from the cytoplasm [131]. 
The membrane permeabilisation effect also has the benefit of making Gram-negative bacteria more 
susceptible to hydrophobic antimicrobials for example erythromycin [132–134]. Polymyxins also have 
the benefit of binding to and neutralizing Gram-negative endotoxins [135,136]. However the systemic 
use of polymyxins is limited with nephrotoxicity, ototoxicity and neurotoxicity common [137–139]. 
Colistin  methanesulphonate,  a  prodrug  of  colistin,  has  shown  increased  use  therapeutically  due 
possessing a lower toxicity profile than colistin itself [140]. 
2. Mechanism of Action of Antimicrobial Peptides  
2.1. Targeting of the Microbial Cell Membrane  
As  with  the  majority  of  antimicrobials,  interaction  with  the  cell  membrane  of  microorganisms  
is fundamental to the mode of action of cationic antimicrobial peptides. The significant difference  
in  the  compositions  of  eukaryotic  membranes  in  comparison  to  prokaryotic  membranes  highlights  
the  important  selectivity  of  cationic  antimicrobials  for  bacterial  cells.  Phospatidylcholine, 
phosphatidylethanolamine,  an  analogue  of  phospatidylcholine,  sphingomyelin  together  with  the 
sterols, ergosterol and cholesterol are predominantly found in eukaryotes and normally have no net 
charge  leading  to  an  overall  neutrally  charged  phospholipid  bilayer.  In  comparison  prokaryotic 
bacterial  cytoplasmic  membranes  are  negatively  charged,  with  a  high  electrical  potential  gradient, 
contributed in part to the presence of acidic hydroxylated phospholipids such as phosphatidylglycerol, 
cardiolipin and phosphatidylserine [12]. Cationic antimicrobial peptides will therefore bind preferentially 
to the negatively charged phospholipid bilayer of bacterial cells [34,141]. This is advantageous with 
regard to reducing toxicity in any potential therapeutic environment. The lack of specific receptors will 
also make it difficult for bacteria to develop resistance to the peptide. Bacteria would have to alter the 
properties of their membrane as a whole rather than specific receptors. The overall positive charge 
associated  with  cationic  antimicrobial  peptides  means  that  initial  electrostatic  interaction  with  the 
bacterial cell membrane will involve areas of dense anionic charge. Acidic polymers such as teichoic Int. J. Mol. Sci. 2011, 12                       
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acids in Gram-positive [142] and phosphate groups present on lipopolysaccharides in Gram-negative 
bacteria  [143]  allow  attachment  of  the  peptide  prior  to  formation  of  transmembrane  pores  and 
ultimately membrane permeabilization.  
Fungal cell membranes tend to share similar properties to the zwitterionic eukaryotic membranes [144]. 
Peptides that primarily possess antifungal activity tend to consist of neutral amino acids with regions 
of  high  polarity  suggesting  that  a  unique  structure-activity  relationship  exists  [145].  Proof  of  this 
structure activity relationship and the importance of lipophilic moieties in the peptide structure were 
provided by Lopez-Garcia et al. [146]. They demonstrated that there was a direct correlation between 
the antifungal activity of peptides and the ability of peptides to form aggregative complexes with lipid 
formulations.  Four  main  hypotheses  exist  as  to how  antimicrobial  peptides  achieve  entry  into the 
bacterial  cell  (Figure  2:  part  A–D).  These  are  the  toroidal  pore,  aggregate,  barrel  stave,  and  
carpet models.  
Figure  2.  Proposed  mechanisms  of  action  of  antimicrobial  peptides.  Antimicrobial 
peptides (cylinders) with the charged hydrophilic regions (red) and hydrophobic regions 
(blue).  (A)  The  “aggregate”  model:  the  antimicrobial  peptides  reorient  to  form  an 
aggregate that spans the membrane, composed of peptide and lipid micelle complexes but 
with no particular orientation adopted; (B) The “toroidal pore” model occurs when the 
peptides insert perpendicular to the plane of the lipid bilayer, with hydrophilic groups on 
the  peptide  interacting  with  the  membranous  phospholipid  head  groups  and  the 
hydrophobic regions associating with the lipid core. A lipid bilayer lined pore is created as 
the membrane curves inwards; (C) The “barrel-stave” model also involves insertion of the 
peptides at a perpendicular orientation to the plane of the bilayer but staves are formed in a 
barrel shaped cluster due to hydrophilic portions of the peptide interacting with the lumen 
of  the  pore  and  hydrophobic  regions  of  the  peptide  associating  with  the  lipid  bilayer;  
(D) The “carpet” model involves the aggregation of peptides at a parallel orientation to the 
lipid bilayer with localized carpeting of areas of the membrane. Micelles are formed above 
a critical threshold concentration leading to a detergent-like activity and the formation of 
pores in the membrane. Adapted from Jenssen, Hamill and Hancock 2006 [147]. 
A                           B                              C     D A                           B                              C     D
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The toroidal pore model involves the peptide inserting perpendicular into the cell membrane via 
electrostatic interactions between the hydrophilic regions of the peptide and the phospholipid head of 
the bilayer. Hydrophobic regions of the peptide bend the lipid monolayers forming a central water core 
lined by lipid head groups and inserted peptides [148]. In doing this the membrane bends inwards such 
that the bilayer lines the channel as well as the peptides. A toroidal pore is thus formed by positive 
curvature,  allowing  entry  of  further  antimicrobial  peptide  [149].  In  the  aggregate  model  a  similar 
process  occurs  to  that  of  the  toroidal  pore  model.  However,  peptides  do  not  adopt  any  specific 
orientation upon insertion into the membrane but cover the membrane as an aggregate of peptide and 
lipid micelles [150]. Channels that do form vary greatly, so much that partial membrane insertion may 
lead to the formation of negative curvature and peptide aggregation within the bilayer [151].  
Perpendicular insertion of the peptides forming barrel-like clusters or staves occurs in the barrel-stave 
model  [152].  Pores  can  occur  from  as  little  as  three  peptide  molecules  and  theoretically  to  allow  
these pores to form, peptides must have an amphipathic or hydrophobic α-helix, β-sheet structure or 
both [153]. Usually the barrel-stave model results in a transmembrane pore of unilateral size. Within 
this pore hydrophilic regions of the peptide oppose the lumen, forming the interior and Van der Waal’s 
attractions occurring between the hydrophobic peptide regions and the lipid core [154]. The carpet 
model suggests that peptides accumulate parallel to the membrane with the hydrophobic regions of the 
peptide  associating  with  the  anionic  phospholipid  head  groups  on  the  membrane  surface  and 
hydrophilic regions attracted to the polar solvent [155]. Localization of peptides occurs forming a 
carpet-like coating on the membrane until a threshold concentration is reached. At this threshold a 
detergent-like process occurs with the eventual formation of micelles and transient pores. Disruption of 
the  membrane  structure  leads  to  membrane  disintegration  [156].  It  has  been  hypothesized  that  the 
additional outer lipid membrane present on Gram-negative organisms consisting of lipopolysaccharides 
allows a self-promoted uptake pathway to occur for cationic peptides [157,158]. As the majority of these 
peptides  have  a  high  affinity  for  lipopolysaccharides  they  bind  to  them,  competitively  replacing 
divalent cations such as magnesium and calcium ions from their relative binding sites [159]. Both 
magnesium and calcium ions are required for cell surface stability via the cross-linking of carboxylated 
and phosphorylated head groups of lipids [160]. Removal of these divalent cations leads to distortion 
of the outer membrane forming holes through which further peptide and other small molecules (such as 
conventional antibiotics) can cross. The self-promoted uptake model provides an explanation as to why 
in  Gram-negative  bacteria  many  cationic  antimicrobial  peptides  act  in  synergy  with  conventional 
antibiotics [161].  
Synergy  of  cationic  antimicrobial  peptides  with  standard  antimicrobials  is  not  limited  to  just  
Gram-negative bacteria but has been proven for both Gram-positive [162] and fungi also [163]. A 
similar pattern of membrane disruption has been demonstrated for antimicrobial peptides against a 
range of fungal pathogens. The rabbit α-defensin NP-2, magainin-2 and bovine lactoferrin have been 
shown to cause membrane permeabilization and cell wall damage in Candida albicans [164–166]. The 
antimicrobial lipopeptide iturin, obtained from cultures of Bacillus subtilis, is fungicidal through its 
activity  on  cell  membranes  [167].  Lipopeptide  aggregates  and  lipopeptide/phospholipid  complexes 
form  at  the  peptide-membrane  interface  resulting  in  the  creation  of  ionic  pores  that  allows  the 
increased influx of potassium ions and fungal cell death [168]. These pores may also provide a means 
by which ATP is released from damaged cells. Membrane damage results in leakage and localized Int. J. Mol. Sci. 2011, 12                       
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increases  in  extracellular  ATP  as  the  microbial  membrane  is  damaged  but  intracellular  metabolic 
processes continue. Vylkova et al. hypothesized that this  may  contribute to cell death  in Candida 
albicans and other microorganisms by facilitating further peptide uptake or activating the host’s innate 
immune response with ATP acting as a chemo-attractant at the site of infection [169]. 
2.2. Mechanism of Action of Antimicrobial Peptides: Intracellular Targeting 
Membrane damage is only one of many mechanisms that antimicrobial peptides may possess in 
exerting microbial cell death. In many cases it may not be the principle mechanism. There is increasing 
evidence for intracellular targeting of microbes (Figure 3: part E–I) as both alternative and synergistic 
pathways to membrane rupture and cell lysis. The antimicrobial peptide buforin II, possessing a linear 
proline hinge and containing an amphipathic α-helical peptide, has been proven to translocate across 
the cell membrane without loss of the transmembrane potential and with intracellular contents intact 
even at  five times the MIC. Cellular  function of Escherichia coli  is  inhibited  by accumulation  of 
buforin II in the cytoplasm and via binding to DNA and RNA [170]. Binding to and inhibition of 
cellular nucleic acids by cationic antimicrobial  peptides  is  feasible due to the polyanionic charges 
present in nucleic acids and also some intracellular enzymes [26,171].  
Some antimicrobial peptides such as indolicidin have been demonstrated to penetrate bacterial cell 
membranes rendering them relatively undamaged but with antibacterial activity achieved by inhibition 
of RNA, DNA and protein synthesis [172]. This contrasts to a mainly membrane active targeting of 
fungal cells by indolicidin via direct interactions with the phospholipid bilayer [173]. Other hypotheses 
for intracellular action include stimulation of the autolytic enzyme cascade [174]. Cationic antimicrobial 
peptides,  for example  lactoferrin and  lysozyme, may  mimic the action of β-lactam antibiotics and 
activate autolytic cell wall enzymes such as  muramidases causing  bacteriolysis [175]. Intracellular 
targeting of protein synthesis by degradation of proteins required for DNA replication has been shown 
to be a primary mechanism of action for indolicidin and the pig intestinal peptide PR-39 [176–178]. 
Indolicidin  and  lactoferricin  B  have  also  been  shown  to  induce  filamentation,  a  process  in  which 
bacterial cells continue to elongate but cannot divide as the septum does not develop, and significant 
cell lysis [179–181]. Filamentation results from inhibition of DNA synthesis [182].  
In  mammals  the  antimicrobial  cathelicidin  peptides  LL-37  and  PR-39  have  multiple  membrane  
and  intracellular  mechanisms of action but they  can also mitigate the immune response to foreign 
pathogens  [183,184].  LL-37  induces  the  selective  movement  of  neutrophils,  monocytes  and  CD4  
T-lymphocyte cells allowing an increase in the adaptive and innate immune response [185,186]. The 
porcine peptide PR-39 promotes healing via stimulation of angiogenesis mediated by its degradation of 
hypoxia inducible factor 1a protein [187]. Int. J. Mol. Sci. 2011, 12                       
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Figure 3. The intracellular action of some antimicrobial peptides (E−I). (E) Dermaseptin, 
buforin-II and pleurocidin are antimicrobial peptides that have been shown to inhibit both 
DNA and RNA synthesis at MIC values [188]. Dermaseptin inhibits RNA synthesis in 
bacteria at MIC concentration or higher within 5 minutes, with lack of bactericidal action 
within  30  minutes  in  Escherichia  coli  evidence  of  a  mainly  intracellular  action  [189]. 
Buforin-II  contains  a  single  proline  residue  within  its  primary  structure  that  allows 
translocation  across  cell  membranes  without  membrane  destruction,  with  binding  to 
nucleic acids resulting in cell death [170,190]; (F) PR-39 and indolicidin have been shown 
to inhibit the rate of protein synthesis and is therefore a plausible target for antimicrobial 
peptides [13,180,191]; (G) Pyrrhocoricin and drosocin act one step later than the molecules 
of  part  E  (dermaseptin,  buforin-II  and  pleurocidin)  and  have  been  shown  to  reduce 
enzymatic activity via inhibition of ATPase activity of the heat-shock protein DnaK, an 
enzyme involved in chaperone-assisted protein folding [192–194]. Otvos and colleagues 
formed a chimeric dimer, with newly formed activity against Staphylococcus aureus and 
increased activity against previously sensitive Escherichia coli, by synthesizing a molecule 
that  possessed  pyrrhocoricin’s  DnaK  binding  domain  and  drosocin’s  high  membrane 
permeating  ability  [195];  (H)  Antimicrobial  peptides  may  also  inhibit  resistance 
mechanisms linked to bacterial pathogenesis for example enzymes with anionic binding 
site pockets linked to the modification of aminoglycoside antibiotics [171]; (I) Lantibiotics 
such  as  mersacidin  and  nisin  target the  formation of  structural  components  of  the  cell  
wall,  specifically  the  transglycosylation  of  lipid  II,  necessary  for  the  synthesis  of 
peptidoglycan [196,197]. Adapted from Jenssen, Hamill and Hancock 2006 [147]. 
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Alternative bactericidal intracellular mechanisms are outlined in Figure 3: parts E-I. By possessing 
multiple microbial targets, antimicrobial peptides can be a therapeutically valuable tool as the potential 
for microbial resistance is low (perhaps negligible). The chances of resistance developing is lessened 
further  by  many  antimicrobial  peptides  possessing  similar  MIC  and  minimum  bactericidal 
concentration (MBC) values (MBC no more than double the value obtained for MIC), owing to mainly 
bactericidal action [198]. The intracellular  mode of action of antimicrobial peptides against fungal 
pathogens is linked to interactions with the fungal mitochondrion, with targeting and perturbation of 
the  mitochondrial  membrane  shown  by  Helmerhorst  et  al.  [199].  The  cationic  peptides  histatins, 
derived from the saliva of humans, bind to receptors present on the fungal cell membrane and when 
present in the cytoplasm they target fungal mitochondria [200]. The echinocandins are an antimicrobial 
peptide family sourced from Aspergillus nidulans that includes the peptides anidulafungin caspofungin, 
and micafungin [201]. They have been shown to inhibit β-(1,3)-glucan synthase, an enzyme responsible 
for the production of the essential fungal cell wall component β-(1,3)-glucan [202–204]. 
3. Development of Resistance to Antimicrobial Peptides 
The  multiple  modes  of  action  utilized  by  antimicrobial  peptides  reduces  the  ability  of 
microorganisms  to  develop  resistance,  with  cidal  activity  also  shown  against  bacteria  resistant  to 
standard antibiotics [205]. The formation of a highly hydrated extracellular polymeric phenotype or 
biofilm contributes to antimicrobial resistance by blocking the transport of antimicrobials through the 
biofilm matrix. Possible mechanisms for this to occur are by binding of the biofilm to them directly, as 
in  the  case  of  positively  charged  aminoglycoside  antibiotics,  restricting  their  permeation  and  by 
restricting diffusion of larger antimicrobials [206,207]. 
Extracellular DNA may also play a role in increased resistance of biofilm forms of Pseudomonas 
aeruginosa against cationic antimicrobial peptides. Extracellular DNA is a cation chelator and acts to 
sequester cations from the surrounding environment and also plays a role in the modification of the 
cationic antimicrobial peptide binding site lipid A by the sugar dehydrogenases enzyme Undecaprenyl 
phosphate-glucose  dehydrogenase  and  covalent  binding  to  4-amino-4-deoxy-L-arabinose  [208]. 
Resistance is conferred via covalent modification of the cationic antimicrobial binding site lipid A. 
Lipid A is a hydrophobic anchor situated on the outer surface of the inner membrane of Gram-negative 
bacteria  and  acts  as  an  anionic  membrane  target  for  cationic  drugs  such  as  polymyxin  and  also  
cationic  antimicrobial  peptides.  Covalent  binding  to  4-amino-4-deoxy-L-arabinose  moiety  reduces 
both the anionic charge of lipid A and its affinity for cationic antimicrobials. In Gram-negative bacteria 
such  as  Escherichia  coli  the  expression  of  genes  (arn  and  ugd  operons)  involved  in  Undecaprenyl 
phosphate-4-amino-4-deoxy-L-arabinose  production  are  controlled  by  the  two  component  quorum 
sensing  systems  PhoP/PhoQ  and  PmrA/PmrB;  and/or  the  RcsA/RcsB/RcsC  system  as  outlined  in  
Figures 4, 5 and 6.  Int. J. Mol. Sci. 2011, 12                       
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Figure 4. The synthesis of Undecaprenyl phosphate-glucuronic acid via quorum sensing 
systems. The two component quorum sensing systems PhoP/PhoQ and PmrA/PmrB; or the 
RcsA/RcsB/RcsC  system  alone  allow  the  expression  of  genes  (ugd)  involved  in  the 
intracellular  synthesis  of  the  4-amino-4-deoxy-L-arabinose  precursor:  Undecaprenyl 
phosphate-glucuronic acid. Both scenarios involve the phosphorylation of the protein Ugd 
by the membrane bound autophosphorylated protein-tyrosine kinase Wzc and/or Etk. Etk 
and Wzc are a BY-kinase (a newly defined group of enzymes involved in protein-tyrosine 
phosphorylation) of Escherichia coli and are involved in the production of the group IV 
capsule  surrounding  the  cell  membrane  [209].  The  wca  operon  is  upregulated  by  the 
RcsA/RcsB/RcsC  system  and  consists  of  19  genes  with  the  third  gene  in  order  of 
transcription  being  the  wzc  gene  that  has  been  shown  to  encode  a  membrane  bound 
autophosphorylated protein-tyrosine kinase Wzc [210]. Etk is coded for by the etk gene 
present  on  the  ymc  operon  of  some  pathogenic  strains  of  Escherichia  coli  [211].  The 
mechanism of the ymc operon is itself unknown, although it could possibly be a promoter 
of etk expression. Key: UDP: Undecaprenyl phosphate. (Adapted from Lacour, 2008 [212]) 
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Figure  5.  The  synthesis  of  Undecaprenyl  Phosphate-α-4-amino-4-deoxy-L-arabinose  
from  Undecaprenyl-Glucuronic  acid.  The  enzymes  ArnA,  ArnB,  ArnC  and  ArnT  are 
produced  by  transcription  of  the  arn  operon  which  is  upregulated  by  the  
RcsA/RcsB/RcsC and PmrA/PmrB quorum sensing systems. The enzyme ArnA catalyses 
the  oxidative  decarboxylation  of  Undecaprenyl  -glucuronic  acid,  thus  forming  an 
Undecaprenyl  -4-keto-pyranose  intermediate.  ArnC  catalyzes  the  transfer  of  the  
4-amino-4-deoxy-L-arabinose moiety to Undecaprenyl phosphate in the inner membrane, 
forming  the  Undecaprenyl  phosphate-α-4-amino-4-deoxy-L-arabinose.  Key:  UDP: 
Undecaprenyl phosphate. (Adapted from Lacour,S. 2008 [212]). 
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Figure  6.  The  transfer  of  4-amino-4-deoxy-L-arabinose  moiety  to  Lipid  A.  
Translocation  to  the  outer  surface  of  the  inner  membrane  occurs  via  an  unknown 
mechanism.  ArnT transfer the 4-amino-4-deoxy-L-arabinose  moiety  from Undecaprenyl  
phosphate-α-4-amino-4-deoxy-L-arabinose  to  Lipid  A,  thereby  reducing  the  affinity  of 
Lipid A for polymyxin and other cationic antimicrobial peptides. (Adapted from Lacour, S. 
2008 [212]). 
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4. Future Perspectives 
As  biocides  antimicrobial  peptides  have  the  potential  to  eradicate  the  most  resistant  forms  of 
clinically relevant biofilm forming pathogens. Lipopeptides such as polymyxin B and daptomycin are 
already  utilized  in  topical  formulations  [213],  therefore  the  potential  exists  for  the  ornithine  and 
tryptophan containing peptides to be exploited similarly. More advanced forms of topical treatment 
would  mimic  the  use  of  the  polycationic  lipopeptide  colistin  and  the  polycationic  trisaccharides 
tobramycin and gentamicin as aerosol therapy for the treatment of persistent lung infections in cystic 
fibrosis patients [214,215]. The potential for natural and synthetic peptides as therapeutic molecules go 
beyond  the  boundaries  of  microbial  biofilm  infection.  Research  has  extended  to  the  use  of  these 
peptides from areas as diverse as cancer treatment [216], to the eradication of sexually transmitted 
diseases [217], such as HIV [218], with a dual role as an effective contraceptive spermicide [219,220]. 
A  group of  cationic  peptides,  referred  to  as  cell-penetrating  peptides  can  translocate  into the  cell 
cytoplasm without disruption of the cell membrane. Peptides such as Apidaecins have the potential to 
act as precursors for the transport of alternative drugs to mammalian cells [221]. Despite the fact there 
are  thousands  of  naturally  sourced  antimicrobial  peptides  and  millions  of  potential  synthetic 
possibilities  there  have  been  limited  clinical  trials  based  on  antimicrobial  peptides  [222].  Only  a Int. J. Mol. Sci. 2011, 12                       
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relative few, for example daptomycin, have entered into clinical trials and therapeutic use based on 
in vitro results and animal studies [106,223,224]. Issues still remain with regard to the stability of 
peptide based formulations in vivo and the large scale production costs of these peptides. It is expected 
that future research will allow the area of antimicrobial peptides to be harnessed therapeutically with 
the  same  degree  of  evolutionary  success  as  they  are  utilized  in  nature  as  components  of  innate 
immunity.  Antimicrobial peptides fulfill a number of the criteria expected from an ‘ideal’ biocide, 
namely performance (high cidal activity and a rapid rate of kill across a range of microorganisms), 
environmental fate (facile bioremediation), safety and cost. 
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